CN103211869A - Traditional Chinese medicine eye drops used for treating acute conjunctivitis and preparation method thereof - Google Patents
Traditional Chinese medicine eye drops used for treating acute conjunctivitis and preparation method thereof Download PDFInfo
- Publication number
- CN103211869A CN103211869A CN2013101751855A CN201310175185A CN103211869A CN 103211869 A CN103211869 A CN 103211869A CN 2013101751855 A CN2013101751855 A CN 2013101751855A CN 201310175185 A CN201310175185 A CN 201310175185A CN 103211869 A CN103211869 A CN 103211869A
- Authority
- CN
- China
- Prior art keywords
- eye drop
- ethanol
- group
- chinese medicine
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine eye drops used for treating acute conjunctivitis and a preparation method thereof. The traditional Chinese medicine eye drops are processed and prepared from honeysuckle flower, mulberry leaf and wild chrysanthemum flower in certain proportion, have the effects of clearing away heat and toxic materials, eliminating red and reducing swelling and are applicable to treatment of the acute conjunctivitis. Compared with the prior art, the traditional Chinese medicine eye drops have the advantages that a process is advanced, a clinical pharmacodynamic experiment effect is more remarkable, biological availability is high and no toxic or side effect is produced.
Description
Technical field
The present invention relates to a kind of Chinese medicine eye drop that is used for acute conjunctivitis and preparation method thereof, belong to technical field of traditional Chinese medicine pharmacy.
Technical background
Acute conjunctivitis is ophthalmology common disease, frequently-occurring disease, and its principal character is that onset is anxious, rapid onset, conjunctival congestion and mycopus sexual secretion, and eye has gargalesthesia, foreign body sensation, burn feeling etc.This disease is mainly in spring and autumn, and the reason that causes mostly is due to antibacterial or the viral infection.Drug therapy is mainly western medical treatment and Chinese traditional treatment at present; Mainly based on medicines such as chloromycetin, rifampicin, ciprofloxacins, these medicine side effect are more common for western medical treatment, the serious adverse effects in addition that has, and body easily produces toleration, and is very unfavorable to people's health.The traditional Chinese medical science mainly based on Chinese patent medicine, is used oral medicine always aspect the treatment acute conjunctivitis, onset is slower, and cure rate is very low, easily recurrence.External Chinese medicine eye drop seldom, curative effect is undesirable, can not meet clinical needs.
Present prior art, Chinese patent discloses that (publication number is: CN1943630A) prescription and the technology of " a kind of eye medicinal of preventing and treating conjunctivitis and keratitis and preparation method thereof ", the inventor is through years of researches, find that the preparation that makes with its technology exists: curative effect is undesirable, cure rate is low, easily recurrence; Technology is thicker, and certain toxic and side effects is arranged: eyes are red itches, poor stability, defective such as active constituent content is low.For solving above-mentioned existing in prior technology defective, in the time in recent years, we are by excavating the abundant Chinese medicine resource of motherland, in conjunction with a large amount of Study on clinical pharmacodynamics, invented a kind of Chinese medicine eye drop that is used for acute conjunctivitis, this product " gold leaf eye drop " is that (publication number is: CN1943630A) on the basis of technology at it, grope by a large amount of experiments, discovery makes " extracting honeysuckle carries out percolation with ethanol " in its technology into " extracting honeysuckle adds ethanol 100ml; soak and carried out percolation by an appendix I0 of Chinese Pharmacopoeia version in 2000 percolation with 10 times of amounts of 75% ethanol in 24 hours ", and " add ethanol carry out precipitate with ethanol " in its technology made into " secondary precipitate with ethanol: add ethanol for the first time and make and contain the alcohol amount and reach 65%; add for the second time ethanol make contain the alcohol amount and reach 75% " back we made eye drop according to new technology, (publication number is: CN1943630A) eye drop that forms of the prescription of " a kind of eye medicinal of preventing and treating conjunctivitis and keratitis and preparation method thereof " and prepared is compared with disclosing according to Chinese patent, its clinical pharmacodynamic experiment effect significantly improves, technology is more reasonable, effective ingredient content height, safe without toxic side effect, eyes do not have any discomfort.
Summary of the invention
The objective of the invention is at the existing defective of state of the art, by excavating the abundant Chinese medicine resource of motherland, in conjunction with a large amount of Study on clinical pharmacodynamics, a kind of prescription science, evident in efficacy is provided, and a kind of Chinese medicine eye drop that is used for acute conjunctivitis that human body is had no side effect.
Another object of the present invention provides the preparation method of Chinese medicine eye drop of the present invention.
For achieving the above object, the technical solution used in the present invention is:
The present invention is used for the Chinese medicine eye drop of acute conjunctivitis, and its prescription consists of:
Flos Lonicerae 100g Folium Mori 30g Flos Chrysanthemi Indici 30g.
The preparation method of Chinese medicine eye drop that the present invention is used for acute conjunctivitis is as follows:
More than three the flavor, extracting honeysuckle adds ethanol 100ml, soak and pressed an appendix I0 of Chinese Pharmacopoeia version in 2000 percolation in 24 hours, carry out percolation with 10 times of amounts of 75% ethanol, percolation speed is 1～3ml/ minute. kilogram, collect percolate, residue pressed liquor and percolate merge, and leave standstill 24 hours, filter, decompression recycling ethanol to 50 ℃ records relative density and is 1.1, and is standby; Medicinal residues and Folium Mori, Flos Chrysanthemi Indici decocts with water twice, adds 10 times of amounts of water for the first time, decocts 30 minutes, collect distillate 60-100ml, add 8 times of amounts of water for the second time, decocted 30 minutes, merge decocting liquid twice, filter, being concentrated into 25 ℃, to record relative density be 1.1-1.2, add ethanol and make and contain the alcohol amount and reach 65%, cold preservation 24 hours filters, it is 1.1 that filtrate recycling ethanol to 50 ℃ records relative density, add ethanol and make and contain the alcohol amount and reach 75%, left standstill 24 hours, filter, it is 1.1 that filtrate recycling ethanol to 50 ℃ records relative density, merge extracted twice filtrate and distillate, add greening sodium 6g, ethyl hydroxybenzoate 0.2g, stirring makes dissolving, adding distil water is to 1000ml, and reconciling pH with 5% sodium hydroxide solution is 6.5-7.5, adds 0.2% active carbon again and boils 10 minutes, filter, packing, sterilization promptly gets eye drop.
The Pharmacodynamic test of active extract data:
The nomenclature of drug of Chinese medicine composition of the present invention is: the gold leaf eye drop.
The test medicine:
1, the present invention tests the preparation (gold leaf eye drop of the present invention) with medicine, is example with gold leaf eye drop of the present invention, and specifically prescription and preparation technology see embodiment 1.
2, contrast medicine (former invention eye drop group): disclose according to Chinese patent that (publication number is: CN1943630A) prescription and the prepared of the embodiment 1 of " a kind of eye medicinal of preventing and treating conjunctivitis and keratitis and preparation method thereof "; Specific as follows:
Prescription: Flos Lonicerae 1000g Folium Mori 300g Flos Chrysanthemi Indici 300g
Add eye medicinal liquid preparation substrate to 10000ml
Preparation method:
A: extracting honeysuckle carries out percolation with ethanol, collects percolate, leaves standstill 24 hours, filters, and reclaims ethanol to relative density and is 1.1 (50 ℃), and is standby;
B: Flos Lonicerae residue, Folium Mori, the Flos Chrysanthemi Indici got behind the percolation add water, decoct, and filter, and repetitive operation 3 times merges 3 times filtrate, and being concentrated into relative density is 1.1-1.2 (25 ℃), and add ethanol and carry out precipitate with ethanol, filtration, filtrate recycling ethanol, standby;
C: preparation eye medicinal preparation substrate: get water for injection, add pleasing to the eye isoosmotic adjusting agent, the preserved ophthalmic antibacterial used, stir and make dissolving, filter filtrate for later use;
D: the filtrate that A and B are made is added in the C filtrate, stirs, and benefit adds to the full amount of water for injection, and filters, and the clear and bright eye drop body preparation of water solublity is promptly made in fill.
Experiment purpose: by pharmacological experiment study to effects such as the microcirculation improvement of gold leaf eye drop of the present invention and former invention eye drop, antiinflammatory, human body immunity improving power and treatment conjunctiva inflammation, gold leaf eye drop of the present invention and former invention eye drop are compared, observe the power of its pharmacological action.
Test method: gold leaf eye drop group of the present invention and former invention eye drop group are to the influence of rabbit eye conjunctivitis disease due to the Oleum Tiglii; To the microcirculatory influence of tame lagophthalmos conjunctiva; The influence of xylol induced mice auricle edema; Influence to the mouse peritoneal capillary permeability; Influence to trinitro-chlorobenzene induced mice ear delayed hypersensitivity; Turnover of Mouse Peritoneal Macrophages is engulfed the influence of chicken red blood cell ability.
One, to the influence of rabbit eye conjunctivitis disease due to the Oleum Tiglii
Experiment material
1, animal: rabbit, male and female have concurrently, body weight 1.8～2.2kg.
2, medicine: former invention eye drop group; Large, medium and small three the dosage groups of gold leaf eye drop of the present invention.
Experimental technique
50 of rabbit, male and female half and half, body weight 1.8～2.2kg is divided into 5 groups at random, 10 every group.Each group is all done the eye conjunctivitis moulding.Fixedly the rabbit head draws back palpebra inferior, and every splashes into 10% Oleum Tiglii proinflammatory agent, 150 μ l, makes it keep using the normal saline flush away behind the 30s in the conjunctiva bag.Respectively at causing 1h, 3h after the scorching moulding, 6h, 24h and 48h.Except that model group splashes into normal saline 150 μ l/, all the other each groups splash into eye drop respectively, and large, medium and small three the dosage groups of gold leaf eye drop group of the present invention only splash into administration 0.012,0.006,0.003g crude drug/kg/ respectively; Former invention eye drop group only splashes into administration 0.012g crude drug/kg/.Show according to eye inflammation: shed tears, secretions thickness, conjunctival congestion, edema corneal edema.Press Ministry of Public Health bureau of drug administration " study of tcm new drug guide " they " eye irritant reaction standards of grading ", each time period eye conjunctiva inflammation degree is marked.Experimental result: see Table 1
Rabbit is with the influence of conjunctiva inflammation due to the table 1 pair Oleum Tiglii
Compare * * P＜0.01 with model group; With former invention eye drop group than △ P＜0.05.
The result shows: gold leaf eye drop group of the present invention and former invention eye drop group 6h after causing inflammation can obviously suppress eye inflammation, with matched group utmost point significant difference (P＜0.01) is arranged relatively; The heavy dose of group of the gold leaf eye drop of the present invention significant difference (P＜0.05) of having compared with former invention eye drop group.As seen, gold leaf eye drop group of the present invention is stronger than the effect of former invention eye drop group treatment eye conjunctivitis.
Two, to the microcirculatory influence of tame lagophthalmos conjunctiva
1, animal: rabbit, male and female have concurrently, body weight 1.8～2.2kg.
2, medicine: former invention eye drop group; Large, medium and small three the dosage groups of gold leaf eye drop of the present invention.
Experimental technique
Adopt tame lagophthalmos conjunctiva blood capillary fluorimetry.50 of rabbit, male and female half and half, body weight 1.8～2.2kg is divided into 5 groups at random, 10 every group.Matched group only splashes into normal saline 150 μ l/; Large, medium and small three the dosage groups of gold leaf eye drop group of the present invention only splash into administration 0.012,0.006,0.003g crude drug/kg/ respectively; Former invention eye drop group only splashes into administration 0.012g crude drug/kg/.Successive administration 3d, every day 1 time, 1h after the last administration, the uranin normal saline solution 1ml/kg (being equivalent to fluorescein 100mg/kg) of tame rabbit ear vein injection 10%, the fluorescence time appears in the record rabbit conjunctival.Experimental result: see Table 2
The table 2 pair microcirculatory influence of tame lagophthalmos conjunctiva
Compare * * P＜0.01 with matched group; With former invention eye drop group than △ P＜0.05.
The result shows: gold leaf eye drop group of the present invention and former invention eye drop group are obviously quickened tame lagophthalmos conjunctiva microcirculation blood flow, promote the ocular blood circulation, have compared utmost point significant difference (P＜0.01) with matched group; The heavy dose of group of the gold leaf eye drop of the present invention significant difference (P＜0.05) of having compared with former invention eye drop group.As seen, gold leaf eye drop group of the present invention is stronger than the microcirculatory effect of former invention eye drop group improvement eye conjunctiva.
Three, the influence of xylol induced mice auricle edema
Experiment material
1, animal: Kunming mouse, male and female half and half, body weight 18～22g.
2, medicine: former invention eye drop group; Large, medium and small three the dosage groups of gold leaf eye drop of the present invention.
Experimental technique
50 of Kunming mouses, male and female half and half, body weight 18～22g is divided into 5 groups at random, 10 every group.Matched group only splashes into normal saline 50 μ l/; Large, medium and small three the dosage groups of gold leaf eye drop group of the present invention only splash into administration 0.04,0.02,0.01g crude drug/kg/ respectively; Former invention eye drop group only splashes into administration 0.04g crude drug/kg/.Successive administration 3d, every day 1 time is after the 3d administration, be coated with dimethylbenzene 0.01ml on ear two sides, a mice left side simultaneously and cause inflammation, cause scorching 30min post-tensioning neck and put to death mice, cut two ears along the auricle baseline, precision claims two auricle weight about it, with the swelling degree of left and right sides auricle weight difference value representation mice ear inflammation.Experimental result: see Table 3
The influence of swelling due to the table 3 pair Mice Auricle dimethylbenzene
Compare * * P＜0.01 with matched group; With former invention eye drop group than △ P＜0.05.
The result shows: gold leaf eye drop group of the present invention and former invention eye drop group can obviously suppress dimethylbenzene induced mice ease auricle swelling, the utmost point significant difference of having compared with matched group (P＜0.01); The heavy dose of group of the gold leaf eye drop of the present invention significant difference (P＜0.05) of having compared with former invention eye drop group.As seen, gold leaf eye drop group of the present invention is stronger than the antiinflammatory action of former invention eye drop group.
Four, to the influence of mouse peritoneal capillary permeability
Experiment material
1, animal: Kunming mouse, male and female half and half, body weight 18～22g.
2, medicine: former invention eye drop group; Large, medium and small three the dosage groups of gold leaf eye drop of the present invention.
Experimental technique
50 of Kunming mouses, male and female half and half, body weight 18～22g is divided into 5 groups at random, 10 every group.Matched group only splashes into normal saline 50 μ l/; Large, medium and small three the dosage groups of gold leaf eye drop group of the present invention only splash into administration 0.04,0.02,0.01g crude drug/kg/ respectively; Former invention eye drop group only splashes into administration 0.04g crude drug/kg/.Successive administration 3d, every day 1 time, behind the 3d administration 1h by mouse tail vein injection 0.5% Yi Wensilan normal saline solution 0.1ml/10kg, the 20min pneumoretroperitoneum is only injected 0.6% acetum 0.2ml/ at interval again, broken end sacrificed by exsanguination mice behind the 20min, cutting the abdominal cavity open washes repeatedly with the 6ml normal saline, and collection eluate, add normal saline and adjust volume to 10ml, the centrifugal 15min of 3000r/min, get supernatant with 722 spectrophotometers in the colorimetric determination of 590nm place, on standard curve, find every mouse peritoneal and infiltrate amount of dye.Experimental result: see Table 4
The influence of table 4 mouse peritoneal capillary permeability
Compare * * P＜0.01 with matched group; With former invention eye drop group than △ P＜0.05.
The result shows: the mouse peritoneal capillary permeability due to gold leaf eye drop group of the present invention and the former invention eye drop group Dichlorodiphenyl Acetate increases has the obvious suppression effect, the utmost point significant difference of having compared with matched group (P＜0.01); The heavy dose of group of the gold leaf eye drop of the present invention significant difference (P＜0.05) of having compared with former invention eye drop group.As seen, gold leaf eye drop group of the present invention than former invention eye drop group antiinflammatory action strong.
Five, to the influence of trinitro-chlorobenzene induced mice ear delayed hypersensitivity
Experiment material
1, animal: Kunming mouse, male and female half and half, body weight 18～22g.
2, medicine: former invention eye drop group; Large, medium and small three the dosage groups of gold leaf eye drop of the present invention.
Experimental technique
50 of Kunming mouses, male and female half and half, body weight 18～22g is divided into 5 groups at random, 10 every group.Matched group only splashes into normal saline 50 μ l/; Large, medium and small three the dosage groups of gold leaf eye drop group of the present invention only splash into administration 0.04,0.02,0.01g crude drug/kg/ respectively; Former invention eye drop group only splashes into administration 0.04g crude drug/kg/.Successive administration 7d, every day 1 time.In second day mouse part skin unhairing of administration, 1h after the administration in the 3rd day, with 2% trinitro-chlorobenzene ethanol liquid 0.05ml/ only, be applied in mouse web portion unhairing position skin, the next day, strengthen once with method, matched group replaces 2% trinitro-chlorobenzene ethanol liquid with ethanol, 1h behind the 7th day medicine of administration, being applied in the mouse right ear two sides with 0.5% trinitro-chlorobenzene Fructus Canarii albi fluid 0.02ml attacks, mice draws neck to put to death behind the 24h, cuts two ears about mice, lays the auricle that diameter is 8mm with card punch, precision is weighed, with mice left and right sides auricle weight difference as mouse ear delayed hypersensitivity intensity.Experimental result: see Table 5
The influence of table 5 pair trinitro-chlorobenzene induced mice ear delayed hypersensitivity
Compare * * P＜0.01 with matched group; With former invention eye drop group than △ P＜0.05.
The result shows: gold leaf eye drop group of the present invention and former invention eye drop group can significantly suppress trinitro-chlorobenzene induced mice delayed hypersensitivity, with matched group utmost point significant difference (P＜0.01) are arranged relatively; Significant difference (P＜0.05) that gold leaf eye drop heavy dose of the present invention is organized and former invention eye drop group has been compared.As seen, gold leaf eye drop group of the present invention is stronger than the effect that former invention eye drop group improves immunity.
Six, Turnover of Mouse Peritoneal Macrophages is engulfed the influence of chicken red blood cell ability
Experiment material
1, animal: Kunming mouse, male and female half and half, body weight 18～22g.
2, medicine: former invention eye drop group; Large, medium and small three the dosage groups of gold leaf eye drop of the present invention.
Experimental technique
50 of Kunming mouses, male and female half and half, body weight 18～22g is divided into 5 groups at random, 10 every group.Matched group only splashes into normal saline 50 μ l/; Large, medium and small three the dosage groups of gold leaf eye drop group of the present invention only splash into administration 0.04,0.02,0.01g crude drug/kg/ respectively; Former invention eye drop group only splashes into administration 0.04g crude drug/kg/.Successive administration 7d, every day 1 time is behind the last administration 2h, the chicken red blood cell 0.4ml of every mouse peritoneal injection 5%, after 12 hours mice is taken off cervical vertebra and put to death, face upward the position and be fixed in the Mus plate, the sterilization abdominal part, cut off skin, through intraperitoneal injection of saline 2ml, rotational fixation plate 1min extracts peritoneal fluid 1ml then, drip and be applied on the microscope slide, every 0.2ml places 37 ℃ of incubator incubation 30min, takes out slide, drop into rinsing in the normal saline, dry, with the fixing 5min of acetone-methanol solution (1: 1), reuse 4% Ji Mu Sa-Rui Teshi liquid dyeing 5min, use the distilled water rinsing, dry.Under oily mirror, count, and calculate the phagocytic index that peritoneal macrophage is engulfed chicken red blood cell.Chicken red blood cell sum/200 that phagocytic index=quilt is engulfed a macrophage experimental result: see Table 6
Table 6 pair Turnover of Mouse Peritoneal Macrophages is engulfed the influence of chicken red blood cell ability
Compare * * P＜0.01 with matched group; With former invention eye drop group than △ P＜0.05.
The result shows: gold leaf eye drop group of the present invention and former invention eye drop group can obviously strengthen the effect of macrophage phagocytic function, have compared utmost point significant difference (P＜0.01) with matched group; The heavy dose of group of the gold leaf eye drop of the present invention significant difference (P＜0.05) of having compared with former invention eye drop group.As seen, gold leaf eye drop group of the present invention is stronger than the effect that former invention eye drop group improves immunity.
Experimental result: gold leaf eye drop group of the present invention and former invention eye drop group can obviously suppress eye inflammation; Obviously quicken tame lagophthalmos conjunctiva microcirculation blood flow, promote the ocular blood circulation; Obviously suppress dimethylbenzene induced mice ease auricle swelling; Mouse peritoneal capillary permeability due to the Dichlorodiphenyl Acetate increases the obvious suppression effect; Significantly suppress trinitro-chlorobenzene induced mice delayed hypersensitivity; Obviously strengthen the effect of macrophage phagocytic function.
Conclusion: gold leaf eye drop of the present invention is stronger than the pharmacological actions such as microcirculation improvement, antiinflammatory, human body immunity improving power and treatment conjunctiva inflammation of former invention eye drop.Therefore, gold leaf eye drop of the present invention clinically is than former invention eye drop heat-clearing and toxic substances removing, and it is strong to move back red repercussive effect.
Acute toxicity testing is the result show: with gold leaf eye drop Cmax of the present invention, maximum volume gastric infusion, successive administration is 3 times in 24h, each 4h at interval, and accumulation medicine total amount reaches 0.28g crude drug/kg, is equivalent to 210 times of clinical plan consumption.In the 7d, mice activity, feed, drainage are all normal after the administration, well-grown, and the hair color light, its average body weight average increases with the prolongation of test period.8d puts to death every mice perusal heart of back dissection, liver, spleen, lung, kidney, brain, thymus, adrenal gland, stomach, intestinal etc. and does not all find color and paramophia.Show that gold leaf eye drop of the present invention does not have acute toxic reaction.
Long term toxicity test is the result show: gold leaf eye drop component of the present invention is that basic, normal, high dosage is respectively 0.04,0.08,0.16g crude drug/kg/d, be equivalent to 30,60,120 times of clinical dosage, gastric infusion is after 12 weeks, gold leaf eye drop of the present invention does not all have tangible influence to general situation, hematological indices, the blood parameters of animal, the yet no abnormal pathological change of system's dissection, organ coefficient and histopathological examination.2 weeks of drug withdrawal are not seen obvious change yet.Gold leaf eye drop of the present invention is not found overt toxicity reaction and delayed toxicity reaction in long term toxicity test.As seen, gold leaf eye drop non-toxic reaction of the present invention, long-term prescription is safe and reliable.
Embodiment 1:
Prescription:
Flos Lonicerae 100g Folium Mori 30g Flos Chrysanthemi Indici 30g.
Preparation method is:
More than three the flavor, extracting honeysuckle adds ethanol 100ml, soak and pressed an appendix I0 of Chinese Pharmacopoeia version in 2000 percolation in 24 hours, carry out percolation with 10 times of amounts of 75% ethanol, percolation speed is 1～3ml/ minute. kilogram, collect percolate, residue pressed liquor and percolate merge, and leave standstill 24 hours, filter, decompression recycling ethanol to 50 ℃ records relative density and is 1.1, and is standby; Medicinal residues and Folium Mori, Flos Chrysanthemi Indici decocts with water twice, adds 10 times of amounts of water for the first time, decocts 30 minutes, collect distillate 60-100ml, add 8 times of amounts of water for the second time, decocted 30 minutes, merge decocting liquid twice, filter, being concentrated into 25 ℃, to record relative density be 1.1-1.2, add ethanol and make and contain the alcohol amount and reach 65%, cold preservation 24 hours filters, it is 1.1 that filtrate recycling ethanol to 50 ℃ records relative density, add ethanol and make and contain the alcohol amount and reach 75%, left standstill 24 hours, filter, it is 1.1 that filtrate recycling ethanol to 50 ℃ records relative density, merge extracted twice filtrate and distillate, add greening sodium 6g, ethyl hydroxybenzoate 0.2g, stirring makes dissolving, adding distil water is to 1000ml, and reconciling pH with 5% sodium hydroxide solution is 6.5-7.5, adds 0.2% active carbon again and boils 10 minutes, filter, packing, sterilization promptly gets eye drop.
Claims (1)
1. a preparation method that is used for the Chinese medicine eye drop of acute conjunctivitis is characterized in that the crude drug weight proportion of described Chinese medicine eye drop is: Flos Lonicerae 100g Folium Mori 30g Flos Chrysanthemi Indici 30g;
Preparation method is: above three flavors, extracting honeysuckle adds ethanol 100ml, soak and pressed appendix 10 percolations of Chinese Pharmacopoeia version in 2000 in 24 hours, carry out percolation with 10 times of amounts of 75% ethanol, percolation speed is 1～3ml/ minute. kilogram, collect percolate, residue pressed liquor and percolate merge, and leave standstill 24 hours, filter, decompression recycling ethanol to 50 ℃ records relative density and is 1.1, and is standby; Medicinal residues and Folium Mori, Flos Chrysanthemi Indici decocts with water twice, adds 10 times of amounts of water for the first time, decocts 30 minutes, collect distillate 60-100ml, add 8 times of amounts of water for the second time, decocted 30 minutes, merge decocting liquid twice, filter, being concentrated into 25 ℃ of C, to record relative density be 1.1-1.2, add ethanol and make and contain the alcohol amount and reach 65%, cold preservation 24 hours filters, it is 1.1 that filtrate recycling ethanol to 50 ℃ records relative density, add ethanol and make and contain the alcohol amount and reach 75%, left standstill 24 hours, filter, it is 1.1 that filtrate recycling ethanol to 50 ℃ records relative density, merge extracted twice filtrate and distillate, add greening sodium 6g, ethyl hydroxybenzoate 0.2g, stirring makes dissolving, adding distil water is to 1000ml, and reconciling pH with 5% sodium hydroxide solution is 6.5-7.5, adds 0.2% active carbon again and boils 10 minutes, filter, packing, sterilization promptly gets eye drop.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101751855A CN103211869B (en) | 2013-05-13 | 2013-05-13 | Traditional Chinese medicine eye drops used for treating acute conjunctivitis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013101751855A CN103211869B (en) | 2013-05-13 | 2013-05-13 | Traditional Chinese medicine eye drops used for treating acute conjunctivitis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103211869A true CN103211869A (en) | 2013-07-24 |
| CN103211869B CN103211869B (en) | 2013-12-04 |
Family
ID=48810255
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013101751855A Active CN103211869B (en) | 2013-05-13 | 2013-05-13 | Traditional Chinese medicine eye drops used for treating acute conjunctivitis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103211869B (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520552A (en) * | 2013-10-25 | 2014-01-22 | 李佃场 | Traditional Chinese medicine composition for treating acute conjunctivitis and preparation method thereof |
| CN105106318A (en) * | 2015-09-15 | 2015-12-02 | 北京市眼科研究所 | Traditional Chinese medicine composition for treating xerophthalmia and preparation method of traditional Chinese medicine composition |
| CN105560891A (en) * | 2016-01-13 | 2016-05-11 | 成都大学 | Traditional Chinese medicine eye drops containing borneol and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105031457A (en) * | 2015-09-20 | 2015-11-11 | 南京正宽医药科技有限公司 | Eye drops for treating conjunctivitis |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1100953A (en) * | 1994-06-14 | 1995-04-05 | 咸阳市第三制药厂 | Eyedrops |
| CN1943630A (en) * | 2005-10-08 | 2007-04-11 | 曾雄辉 | Eye medicine for preventing and treating conjunctivitis and keratitis and its preparing method |
-
2013
- 2013-05-13 CN CN2013101751855A patent/CN103211869B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1100953A (en) * | 1994-06-14 | 1995-04-05 | 咸阳市第三制药厂 | Eyedrops |
| CN1943630A (en) * | 2005-10-08 | 2007-04-11 | 曾雄辉 | Eye medicine for preventing and treating conjunctivitis and keratitis and its preparing method |
Non-Patent Citations (1)
| Title |
|---|
| 梁杰: "试论急性结膜炎证治", 《云南中医中药杂志》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103520552A (en) * | 2013-10-25 | 2014-01-22 | 李佃场 | Traditional Chinese medicine composition for treating acute conjunctivitis and preparation method thereof |
| CN103520552B (en) * | 2013-10-25 | 2015-04-22 | 青岛市中心医院 | Traditional Chinese medicine composition for treating acute conjunctivitis and preparation method thereof |
| CN105106318A (en) * | 2015-09-15 | 2015-12-02 | 北京市眼科研究所 | Traditional Chinese medicine composition for treating xerophthalmia and preparation method of traditional Chinese medicine composition |
| CN105106318B (en) * | 2015-09-15 | 2018-10-19 | 北京市眼科研究所 | A kind of Chinese medicine composition and preparation method thereof for treating xerophthalmia |
| CN105560891A (en) * | 2016-01-13 | 2016-05-11 | 成都大学 | Traditional Chinese medicine eye drops containing borneol and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103211869B (en) | 2013-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103211869B (en) | Traditional Chinese medicine eye drops used for treating acute conjunctivitis and preparation method thereof | |
| CN102416106B (en) | Chinese medicinal composition for treating middle-aged and senile eye disease and preparation method thereof | |
| CN104958445A (en) | Chastetree fruit oral liquid for preventing wind-heat upward attacking and swelling and pain of eyes, and preparation method of chastetree fruit oral liquid | |
| CN103301146A (en) | Traditional Chinese medicine monomer combination capable of resisting oxidation and improving eyeground blood circulation | |
| CN102319398B (en) | Blood-nourishing and eyesight-improving Chinese medicinal composition and preparation method thereof | |
| CN103169787A (en) | Composition with functions of improving sleep quality and extending deep sleep time and application thereof | |
| CN103405680B (en) | Traditional Chinese medicine decoction used for treatment of herpes zoster around eyes | |
| CN101361892B (en) | Traditional Chinese medicine formulation for treating cataract and preparation method thereof | |
| CN105125984B (en) | A kind of aqueous Chinese medicine plaster for external application for treating infantile cough | |
| CN102293847B (en) | Chinese medicinal composition for treating constipation, acne and hyperlipidemia, and preparation method | |
| CN109512870B (en) | Pharmaceutical composition, preparation method and application thereof | |
| CN103006831B (en) | Blood platelet raising capsules, namely Chinese herbal combination, and preparation method of capsules | |
| CN105535484A (en) | Towel gourd and traditional Chinese medicine mask with freckle removing and skin beautifying functions and preparing method thereof | |
| CN102078509B (en) | Traditional Chinese medicine preparation for treating ophthalmorrhagia and preparation method thereof | |
| CN107982484A (en) | Treat Chinese medicinal compound extract of diabetic retinopathy and its preparation method and application | |
| CN100500174C (en) | Medicine composition used for lowering blood-sugar, preparation method and use thereof | |
| CN103784579A (en) | Traditional Chinese medicinal composition for inflammation diminishing, eyesight improving and pain relieving, and preparation method thereof | |
| CN103463244A (en) | Method for extracting blood sugar lowering substance from China roses and application of blood sugar lowering substance | |
| CN103549072B (en) | Vital energy-benefiting brain-boosting tea and preparation method thereof | |
| CN104306546B (en) | A kind of Chinese medicine composition and its decoction, pill and powder for being used to treat optic atrophy | |
| CN103566227B (en) | A kind of Chinese medicine composition preventing and treating type 2 diabetes mellitus and preparation method thereof | |
| CN107648397B (en) | Traditional Chinese medicine composition for treating liver-kidney yin deficiency and preparation method and application thereof | |
| CN100389782C (en) | Eyesight-improving capsule and preparation process thereof | |
| CN1857531A (en) | Recipe, preparing process and application of Chinese medicine preparation for treating diabetic retinopathy | |
| CN103989940A (en) | Traditional Chinese medicine composition for treating diabetes mellitus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 710400 Ma Zhao section 1420, national highway 108, Zhouzhi County, Xi'an City, Shaanxi Province Patentee after: Zhouzhi Qingbao Pharmaceutical Co.,Ltd. Address before: Room A1604, Cross High Tech Building, Xiyang Village, Weiyang West Road, Xianyang City, Shaanxi Province, 712000 Patentee before: SHAANXI LIZHONG PHARMACEUTICAL Co.,Ltd. |